- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07232069
Prosjektiv Randomisert Evaluering og Behandling av Tidlig Aterosklerose (PRE-EMPT) (PRE-EMPT)
Prospektiv Randomisert Vurdering og Behandling av Tidlig Aterosklerose
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Rachel Olson, Project Manager
- Telefonnummer: 919-309-5544
- E-post: rachel.e.olson@duke.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35205
- Rekruttering
- University of Alabama at Birmingham
-
Hovedetterforsker:
- Kevin Riggs, MD
-
Ta kontakt med:
- Dalton Norwood
- Telefonnummer: 909-786-8315
- E-post: daltonnorwood@uabmc.edu
-
Mobile, Alabama, Forente stater, 36608
- Rekruttering
- Cardiology Associates
-
Ta kontakt med:
- Lynn Ward, RN BSN CCRC
- Telefonnummer: 251-607-9797
- E-post: lynnward@cardassoc.com
-
Hovedetterforsker:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California, Los Angeles
-
Ta kontakt med:
- Lynae Edmunds
- Telefonnummer: 310--210-9806
- E-post: laedmunds@mednet.ucla.edu
-
Hovedetterforsker:
- Karol Watson, MD
-
Los Angeles, California, Forente stater, 90502
- Rekruttering
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
Ta kontakt med:
- Sajad Hamal
- Telefonnummer: 310-974-9336
- E-post: shamal@lundquist.org
-
Hovedetterforsker:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, Forente stater, 30141
- Rekruttering
- Wellstar Kennestone Hospital
-
Hovedetterforsker:
- Frank Corrigan, MD
-
Ta kontakt med:
- Frank Corrigan, MD
- Telefonnummer: 678-324-4444
- E-post: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Hovedetterforsker:
- Tamar Polonsky, MD
-
Ta kontakt med:
- Tamar Polonsky, MD
- Telefonnummer: 773-702-1409
- E-post: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Har ikke rekruttert ennå
- Johns Hopkins University
-
Ta kontakt med:
- Prati Pratishruti, MBBS
- Telefonnummer: 410-301-1245
- E-post: fpratis1@jhu.edu
-
Hovedetterforsker:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital Brigham
-
Ta kontakt med:
- Pearl Lee, MSc
- Telefonnummer: 617-721-7783
- E-post: plee23@mgh.harvard.edu
-
Hovedetterforsker:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, Forente stater, 55805
- Rekruttering
- Essentia Health
-
Ta kontakt med:
- Martha Vanderlinde, BS
- Telefonnummer: 218-786-2729
- E-post: Martha.Vanderlinde@essentiahealth.org
-
Hovedetterforsker:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, Forente stater, 10549
- Har ikke rekruttert ennå
- Northern Westchester Hospital
-
Ta kontakt med:
- Dina Katz, MD
- Telefonnummer: 914-762-5810
- E-post: PRE-EMPT@northwell.edu
-
Hovedetterforsker:
- Dina Katz, MD
-
New York, New York, Forente stater, 10021
- Rekruttering
- Weill Cornell Medicine
-
Ta kontakt med:
- Dolores Reynolds, RN
- Telefonnummer: 212-746-4617
- E-post: dtr2001@med.cornell.edu
-
Hovedetterforsker:
- Sam Kim, MD
-
New York, New York, Forente stater, 10016
- Rekruttering
- New York University Langone
-
Hovedetterforsker:
- Harmony Reynolds, MD
-
Ta kontakt med:
- Harmony Reynolds, MD
- Telefonnummer: 212-263-4320
- E-post: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Hospital
-
Hovedetterforsker:
- Nishant Shah, MD
-
Ta kontakt med:
- Niki Huffman
- Telefonnummer: 919-681-6458
- E-post: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Wake Forest University, Advocate Health
-
Hovedetterforsker:
- Michael Shapiro, MD
-
Ta kontakt med:
- Sophia Dawson, BA
- Telefonnummer: 336-713-2338
- E-post: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Har ikke rekruttert ennå
- Oregon Health and Sciences University
-
Ta kontakt med:
- John Halvorson
- Telefonnummer: 503-418-1679
- E-post: halvorsj@ohsu.edu
-
Hovedetterforsker:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Har ikke rekruttert ennå
- Thomas Jefferson University
-
Ta kontakt med:
- Caroline Freeman, BS
- Telefonnummer: 215-792-3872
- E-post: Caroline.Freeman@Jefferson.edu
-
Hovedetterforsker:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- University of Pittsburgh Medical Center
-
Hovedetterforsker:
- Anum Saeed, MD
-
Ta kontakt med:
- Karli Drewencki
- Telefonnummer: 412-647-2931
- E-post: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Medical University of South Carolina (MUSC)
-
Hovedetterforsker:
- Sheldon Litwin, MD
-
Ta kontakt med:
- Melissa Amitrano, MPH
- Telefonnummer: 843-876-5009
- E-post: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Har ikke rekruttert ennå
- Vanderbilt University
-
Hovedetterforsker:
- Deepak Gupta, MD
-
Ta kontakt med:
- Gabriella Davies Thoppil, MD MPH
- Telefonnummer: 615-421-1143
- E-post: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Ta kontakt med:
- Peyton Martin
- Telefonnummer: 443-413-6350
- E-post: knasir@houstonmethodist.org
-
Hovedetterforsker:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22903
- Rekruttering
- University of Virginia (UVA)
-
Ta kontakt med:
- James Ingersoll
- Telefonnummer: 434-982-1058
- E-post: WFC5KC@uvahealth.org
-
Hovedetterforsker:
- Todd Villines, MD
-
Fairfax, Virginia, Forente stater, 22031
- Har ikke rekruttert ennå
- Inova Health System
-
Ta kontakt med:
- Mahira Awan
- Telefonnummer: 571-472-8570
- E-post: mahira.awan@inova.org
-
Hovedetterforsker:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, Forente stater, 54449
- Rekruttering
- Marshfield Clinical Research Institute
-
Ta kontakt med:
- Kelly Scheffen
- Telefonnummer: 715-221-7285
- E-post: preempt@marshfieldresearch.org
-
Hovedetterforsker:
- Jeff VanWormer
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
Andre navn:
Placebo, non-active, drug-matched |
|
Eksperimentell: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
Andre navn:
|
|
Eksperimentell: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
Andre navn:
Anti-inflammatory
Andre navn:
|
|
Placebo komparator: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tidsramme: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endring i LDL-kolesterol (low-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
|
Baseline til 2 år
|
|
|
Endring i ikke-HDL-kolesterol (high-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
|
Baseline til 2 år
|
|
|
Number of participants with Drug Discontinuation
Tidsramme: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
Tidsramme: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
Tidsramme: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
Tidsramme: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
Tidsramme: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
Tidsramme: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
Tidsramme: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
Tidsramme: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tidsramme: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tidsramme: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Farmasøytiske preparater
- Doseringsformer
- Hydrokarboner
- Alkaloider
- Amides
- Pyrimidiner
- Hydrokarboner, halogenert
- Sulfonamider
- Sulfoner
- Fluorbenzener
- Hydrokarboner, fluorert
- Rosuvastatin kalsium
- Kolkisin
- Tabletter
Andre studie-ID-numre
- Pro00118744
- UG3HL181434 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .